Johnson & Johnson (JNJ)

• Market cap: $424B
• 1 day: -0.69%
• 5 days: -0.07%
• 1 month: -0.04%
• 3 months: 13.5%
• 6 months: 8.19%
• Year to date: 22.33%
• 1 year: 5.5%
• 5 years: 18.72%
• 10 years: 86.22%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Employees: 139,800

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

24% more call options, than puts

Call options by funds: $3.06B | Put options by funds: $2.48B

1.93% more ownership

Funds ownership: 70.97% [Q1] → 72.9% (+1.93%) [Q2]

3% less first-time investments, than exits

New positions opened: 172 | Existing positions closed: 177

2% less funds holding

Funds holding: 4,089 [Q1] → 4,008 (-81) [Q2]

6% less capital invested

Capital invested by funds: $283B [Q1] → $267B (-$16.5B) [Q2]

14% less repeat investments, than reductions

Existing positions increased: 1,596 | Existing positions reduced: 1,858

43% less funds holding in top 10

Funds holding in top 10: 225 [Q1] → 128 (-97) [Q2]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $167
• Avg. target: $181
• High target: $200

7 analyst ratings

• positive: 3 43%
• neutral: 4 57%
• negative: 0 0%

Citigroup Joanne Wuensch	$200	Buy Maintained	21 Aug 2025
Barclays Matt Miksic	$176	Equal-Weight Maintained	17 Jul 2025
RBC Capital Shagun Singh	$185	Outperform Maintained	17 Jul 2025
Guggenheim Vamil Divan	$167	Neutral Maintained	17 Jul 2025
UBS Danielle Antalffy	$190	Buy Maintained	17 Jul 2025